Earnings Releases·Nov 3, 2026, 4:05 PM ET

Amgen — Third Quarter 2026 Earnings Summary

Total revenues rose 8% year-over-year to $10.4 billion, while GAAP EPS increased 19% to $7.08 and Non-GAAP EPS rose 14% to $6.45.
Full-year 2026 guidance projects total revenue between $38.9 billion and $39.7 billion, GAAP EPS between $18.34 and $19.28, and Non-GAAP EPS between $22.90 and $23.70.
Strong product performance was led by 17 products with double-digit growth, including Repatha (+37%) and UPLIZNA (+191%), offset by biosimilar competition impacting Prolia (-45%) and XGEVA (-47%).
Capital return strategy includes a 6% dividend increase to $2.52 per share, with full-year share repurchases capped at $3.0 billion and no repurchases executed in Q3.
Strategic outlook remains positive with multiple Phase 3 studies ongoing for MariTide and Dazodalibep, though regulatory headwinds persist regarding TAVNEOS and a partial clinical hold on subcutaneous blinatumomab.